<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01618110</url>
  </required_header>
  <id_info>
    <org_study_id>SH-12-0012</org_study_id>
    <nct_id>NCT01618110</nct_id>
  </id_info>
  <brief_title>Transcranial Magnetic Stimulation in Treatment of Attention Deficit/Hyperactivity Disorders</brief_title>
  <official_title>Transcranial Magnetic Stimulation of the Pre-Frontal Cortex in the Treatment of Attention Deficit/Hyperactivity Disorders: A Randomized, Controlled, Double Blind Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  ADHD is one of the most common psychiatric disorders.

        -  While most of the attention is directed towards youth, 60% continue to suffer symptoms
           into adult life.

        -  Current treatment is effective, but 30% suffer side effects that lowers QOL, and 20% are
           non-responders.

        -  Known mechanism of pathophysiology includes hypoactive dopaminergic system, especially
           at right PFC.

        -  It is this study hypothesis that by stimulating the right PFC by TMS, it will be
           possible to alleviate ADHD symptoms.

        -  A 10 sessions of treatment will by applied on a randomly allocated group of patients,
           diagnosed with ADHD, in a 2:1 ratio: The first group will receive an actual TMS
           treatment, and the second group will receive a sham treatment.

        -  Improvement of objective and subjective ADHD scale will be examined.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Attention Deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham TMS coil (same noise, minimal magnetic field)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Magnetic Stimulation (Magstim, Rapid)</intervention_name>
    <description>Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.</description>
    <arm_group_label>Treatment Group</arm_group_label>
    <other_name>Magstim, Rapid</other_name>
    <other_name>Transcranial Magnetic Stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Treatment</intervention_name>
    <description>Sham coil (minimal magnetic field, same noise and feeling)</description>
    <arm_group_label>Sham group</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-50

          -  Established diagnosis of ADHD

          -  No C/I for TMS

          -  Has signed an informed consent form

        Exclusion Criteria:

          -  Major Psychiatric disorders (Psychotic or Affective)

          -  Active use of drugs (4 weeks prior to participation)

          -  Neurologic disorder such as Epilepsy.

          -  No use of stimulants during the previous 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuval Bloch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shalvata MHC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aviv Segev, MD</last_name>
    <phone>972-9-7478-644</phone>
    <email>aviv.segev@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuval Bloch, MD</last_name>
    <phone>972-9-7478-510</phone>
    <email>yuvalbl@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shalvata MHC</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aviv Segev, MD</last_name>
      <phone>972-9-7478-644</phone>
      <email>aviv.segev@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yuval Bloch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aviv Segev, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2012</study_first_submitted>
  <study_first_submitted_qc>June 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2012</study_first_posted>
  <last_update_submitted>June 18, 2012</last_update_submitted>
  <last_update_submitted_qc>June 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADHD</keyword>
  <keyword>Attention Deficit/Hyperactivity Disorder</keyword>
  <keyword>TMS</keyword>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

